Author: Biotech Express

By Kamal Pratap Singh, Managing Editor- Biotech Express It is shocking to see that one of India’s most revered biotechnologists has been dragged by the Elsevier publishers who have now retracted some of his publications from their journal (Bioresource Technology) for no fault of his. It came to light when the news was published in The Hindu that quoted PubPeer having shared the retracted articles due to ethical misconduct and not scientific misconduct. When one delves into these papers, it is noted that the authors have vehemently denied that retraction but Elsevier which is a multi-billon dollar publisher perhaps due…

By Kamal Pratap Singh, Managing Editor, Biotech Express E-mail- kamal9871@gmail.com Now it is apparent that covishield is indeed responsible for deaths of many who were not subjected to emergency vaccination. The governments and the international organizations including Blackrock, Bill and Melinda Gates foundation forced people to take vaccine for the sake of profit of their partners, one of them is Serum Institute of India (SII). But that is not limited to serum only, Bharat Biotech the other company was also criticized for their low quality as safe as water vaccine. Ethically if we see the history, only one company in…

The 48th Annual meeting and international conference of the Indian Society of Human Genetics, jointly organised by FRIGE’s Institute of Human Genetics and Gujarat Biotechnology Research Centre, was held from Jan 21 to 24, 2024, in Ahmedabad, India. The motto of this year’s event was Sarva mangalam bhavatu, which means peace, health, and prosperity for all. The conference was attended by over 700 delegates, including 130 faculties and 36 biotechnology companies from 13 countries who discussed and deliberated on the progress made in basic genetics, and translational aspects including screening, diagnosis, prevention, and novel treatment approaches in rare genetic disorders.…

Dr. Krishna Ella, Co-founder and Executive Chairman of Bharat Biotech, has been awarded the prestigious Dean’s medal by the Johns Hopkins Bloomberg School of Public Health. The award was presented to Dr. Ella by Dean Ellen J. MacKenzie during Bloomberg School’s Convocation Ceremony on May 22nd, 2024, in Baltimore, Maryland, for his exceptional leadership, enduring vision and contribution to improving public health. John Hopkins Bloomberg School of Public Health acknowledges Dr Ella’s pioneering work, remarkable influence, and determination to develop an indigenous, innovative, and safe vaccine focused on global public health. This is the School’s highest honour, reserved for outstanding…

According to the latest study, the global antibiotics market size is calculated at USD 53.90 billion for 2024 and is expected to reach around USD 85.80 billion by 2033, growing at a CAGR of 5.3% from 2024 to 2033, Asia Pacific accounted for the highest market share of over 46.00% in 2023. The antibiotics market is experiencing rapid growth driven by the increasing demand for medicines that combat bacterial infections in both human and veterinary healthcare settings. These medications function by either eradicating bacteria or inhibiting their proliferation, targeting specific bacterial infections such as strep throat, urinary tract infections, and…

Biocon announced that the U.S. Food and Drug Administration (US FDA) has approved the Company’s first-to-file application for Yesafili™ (aflibercept-jbvf), an interchangeable* biosimilar aflibercept. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat several different types of ophthalmology conditions, is a biosimilar of its reference product EYLEA® (aflibercept). The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States following a steady track record of approval in Europe (September 2023) and the United Kingdom (November 2023) where it was the first biosimilar aflibercept to be approved. The Company has secured a launch…

An HIV vaccine candidate developed at the Duke Human Vaccine Institute triggered low levels of an elusive type of broadly neutralizing HIV antibodies among a small group of people enrolled in a 2019 clinical trial. The finding, reported May 17 in the journal Cell, not only provides proof that a vaccine can elicit these antibodies to fight diverse strains of HIV, but that it can also initiate the process within weeks, setting in motion an essential immune response. The vaccine candidate targets an area on the HIV-1 outer envelope called the membrane proximal external region (MPER), which remains stable even…

The first person to publicly release the genome sequence of the virus that causes COVID-19 — virologist Zhang Yongzhen — seems to have resolved a public dispute with the Shanghai Public Health Clinical Center (SPHCC), Fudan University, China, which erupted last week. According to social-media posts on Zhang’s personal Weibo account, which have since been removed, the institute gave the research team two days to leave, but the SPHCC did not initially specify to where they should relocate. Later, Zhang said that officials told his team to move to a lab that did not have the necessary biosafety conditions to…

MAY 03, 2024 Days after AstraZeneca acknowledged that its COVID vaccine can lead to a rare blood clot side effect, the parents of a young woman who allegedly died after being given Covishield are planning to sue the British pharma giant and world’s largest vaccine maker. The development comes after AstraZeneca admitted in the UK court that their vaccine can cause rare side effects that can lead to blood clots and low platelet count. Notably, while AstraZeneca developed the COVID-19 vaccine, it was manufactured in India by the Serum Institute of India (SII) under the name ‘Covishield’. The vaccine was…

Biological E. Limited (BE), a Hyderabad-based Vaccine and Pharmaceutical Company, announced the publication of Phase-III clinical trials results of BE’s 14-Valent Pneumococcal Conjugate Vaccine (PCV) (PNEUBEVAX 14TM; BE-PCV-14) conducted in paediatric population (6-8-week age group). The study results have been accepted and published by Vaccine, a reputed peer-reviewed international journal. In this study, the immunogenicity and safety of the BE’s 14-Valent PCV containing two additional epidemiologically important serotypes (22F and 33F) were evaluated in infants, in comparison to the licensed comparator vaccine PCV-13. This was a pivotal Phase-III single blind randomized active-controlled study conducted at 12 sites across India in…